

Online Resource 2

Zoledronic Acid and Bone Health in Older Adults with Cognitive Impairment

Bryce M. Churilla, BS^a, Subashan Perera, PhD^{a,b}, Susan L. Greenspan, MD^{a,c}, Neil M. Resnick, MD^a, Mary P. Kotlarczyk, PhD^a

^aDivision of Geriatric Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh PA

^bDepartment of Biostatistics, University of Pittsburgh, Pittsburgh PA

^cDivision of Endocrinology and Metabolism, Department of Medicine, University of Pittsburgh, Pittsburgh PA

Corresponding Author: Mary P. Kotlarczyk, PhD; mpk38@pitt.edu

Supplemental Table 2: Number and Percentage of Distinct Women with Adverse Events or Dropped Out

Event Type	Cognitively Impaired		Cognitively Unimpaired	
	Zoledronic Acid N (%)	Placebo N (%)	Zoledronic Acid N (%)	Placebo N (%)
Any adverse event	20 (95.2)	19 (86.4)	63 (94.0)	63 (91.3)
Serious adverse event	10 (47.6)	7 (31.8)	30 (44.8)	33 (47.8)
Expected side effects*	11 (52.4)	8 (36.4)	26 (38.8)	24 (34.8)
Falls	15 (71.4)	10 (45.5)	36 (53.7)	29 (42.0)
Fractures	1 (4.8)	1 (4.5)	9 (13.4)	5 (7.2)
Death	3 (14.3)	1 (4.5)	3 (4.5)	3 (4.3)
Renal and urinary disorders	2 (9.5)	7 (31.8)	10 (14.9)	14 (20.3)
Dropped out	1 (4.8)	1 (4.5)	4 (6.0)	3 (4.3)

* Pyrexia, myalgia, influenza, influenza-like symptoms, headache, arthralgia, fatigue, diarrhea, nausea, malaise, weakness or musculoskeletal pain